James Douglas Griffin, M.D.
Co-Author
This page shows the publications co-authored by James Griffin and Martin Sattler.
Connection Strength
9.402
-
JAK2 gets histone H3 rolling. Cancer Cell. 2009 Nov 06; 16(5):365-6.
Score: 0.421
-
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 01; 107(3):1237-8.
Score: 0.325
-
Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr; 40(2 Suppl 2):4-10.
Score: 0.267
-
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40.
Score: 0.262
-
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
Score: 0.247
-
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
Score: 0.235
-
Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 Apr; 73(3):278-91.
Score: 0.232
-
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
Score: 0.228
-
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
Score: 0.225
-
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
Score: 0.223
-
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
Score: 0.222
-
Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167.
Score: 0.222
-
Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020 Aug; 98(8):483-489.
Score: 0.221
-
Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
Score: 0.214
-
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
Score: 0.214
-
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
Score: 0.213
-
BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999 Nov; 19(11):7473-80.
Score: 0.211
-
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
Score: 0.208
-
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
Score: 0.206
-
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.
Score: 0.203
-
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther. 2018; 11:175-182.
Score: 0.185
-
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. 2018 02 06; 57(5):477-478.
Score: 0.184
-
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 06; 15(19):2379-84.
Score: 0.183
-
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984.
Score: 0.183
-
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
Score: 0.179
-
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
Score: 0.179
-
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650.
Score: 0.179
-
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6.
Score: 0.178
-
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11; 272(15):10248-53.
Score: 0.176
-
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
Score: 0.176
-
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46.
Score: 0.163
-
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
Score: 0.157
-
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther. 2015 Oct; 14(10):2249-59.
Score: 0.157
-
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015 May 14; 125(20):3133-43.
Score: 0.153
-
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563.
Score: 0.152
-
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95.
Score: 0.147
-
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37.
Score: 0.144
-
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
Score: 0.120
-
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012 Apr; 26(4):708-15.
Score: 0.120
-
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012 Mar; 26(3):481-9.
Score: 0.119
-
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
Score: 0.113
-
Drug resistance in mutant FLT3-positive AML. Oncogene. 2010 Sep 16; 29(37):5120-34.
Score: 0.110
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
Score: 0.110
-
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9.
Score: 0.103
-
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 01; 111(7):3751-9.
Score: 0.093
-
Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006 Jun 30; 281(26):18177-83.
Score: 0.082
-
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
Score: 0.074
-
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92.
Score: 0.063
-
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2022 01; 36(1):210-220.
Score: 0.059
-
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25.
Score: 0.054
-
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
Score: 0.053
-
Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
Score: 0.046
-
BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57.
Score: 0.045
-
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85.
Score: 0.044
-
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6.
Score: 0.043
-
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
Score: 0.043
-
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb; 24(2):310-3.
Score: 0.041
-
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol. 2013 Oct; 20(10):1221-3.
Score: 0.034
-
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
Score: 0.033
-
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44.
Score: 0.031
-
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
Score: 0.027
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
Score: 0.017
-
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
Score: 0.014
-
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
Score: 0.012
-
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
Score: 0.011
-
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.